An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2018
At a glance
- Drugs MDNA 55 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Medicenna Therapeutics
- 27 Jun 2018 According to a Medicenna Therapeutics media release, top-line data from this study is expected in early 2019.
- 15 May 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 15 May 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History